VNX-102
Multiple Myeloma
IND-EnablingActive
Key Facts
About Vironexis Biotherapeutics
Vironexis Biotherapeutics, founded in 2021, is developing a transformative platform for AAV-delivered T-cell immuno-gene therapy. The company's TransJoin™ platform is designed to create off-the-shelf, single-infusion therapies that engineer a patient's T cells in vivo to target and kill cancer cells, bypassing the need for complex ex vivo cell manufacturing. Its pipeline includes over ten preclinical programs targeting blood cancers, solid tumors, and cancer prevention, with its lead asset, VNX-101 for CD19+ leukemias and lymphomas, having received FDA IND clearance and multiple regulatory designations. The company is led by a founding team with deep expertise in gene therapy development and oncology.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |